$XBI closed RED - $SLS Up Big and Green Divergency = a short emergency, 2 Massive Trial Results in 4 or 5 weeks and a Billion Dollar FDA Approval next year. SLS shares are Cheap As F - $50M Market cap when $jazz paid $1.5B for a direct comp, only a matter of time.
Massively undervalued Equity $Jazz paid $1.5B for Cpxx when it released its p3 data. SLS now trades for .0375 or 3.75% of what it will be worth when the AML Approval happens in 12 months no or sooner when the idmc halts the trial for efficacy.
$Jazz paid $1.5B for Cpxx AML agent, similar to Gps P3 market. Equal to $75/sls share +2,770% ROI FDA approval 12 months If Idmc doesn’t halt this sooner.
C
Looking forward to tomorrows earnings report! This is currently one of my few stocks in the green (for now).
T
Interesting Jazz is down $7 pre market. Very bizarre trading all ways around. Maybe a decision is imminent?
Cantor Fitz Analysts proj revenue of $200M in initial Niche cr2 setting. SELLAS is a late-stage immune-oncology company that is focused on novel cancer vaccines. The lead drug candidate, galinpepimut-S (GPS), is a peptide vaccine that target Wilms tumor 1 and is in a Phase 3 trial for acute myeloid leukemia (AML).
Even in the initial niche target population of AML patients after second complete remission, “we project the peak sales to be about $200-million” Li Watsek
“Overtime, we think GPS has the potential to broaden into AML patients after first complete remission, as well as in other indications with combinations”
Gps is Priceless for AML patients. What will big pharma pay for $800M in Potential AML Revenue?
Buy and Hold
Jazz Pharmaceuticals agreed to buy Celator Pharmaceuticals in a roughly $1.5 billion deal that represents a huge premium for a company with a promising leukemia drug but no revenue.
Jazz Pharmaceuticals agreed to buy Celator Pharmaceuticals in a roughly $1.5 billion deal that represents a huge premium for a company with a promising leukemia drug but no revenue.
www.wsj.com
C
So much for this being my only stock that "was" in the green.
A
been holding for months and sold at 156. I feel I have missed something in my understanding on when to sell
Y
Is this the US govt owned stock where they use their patent on pot while making it still illegal for the competition? Yes, YES IT IS!
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
www.globenewswire.com
A
Do you see a bearish divergence or are we building support ?
t
I have many quality stocks this is the only one that was up today every other one was down I’m about ready to cash out and watch
B
Time to buy the puts folks 155 looking tasty. the lawsuit is just the start see you guys sub 100's want to long buy BDX or ABT this thing toast.
C
This is one of the only stocks I own that I like right now and I'm only up 1%. The Cannabis sector has been terrible but this is holding up nice. I plan on holding this for a long time and feel confident unlike most all my holdings.
After CPXX reported its p3 data, Jazz bought Cpxx for $1.5B their AML drug isn't half the drug GPS is - SLS trades for .08B $Jazz Pharmaceuticals said it will acquire Celator in a deal worth a total of $1.5 billion. The Irish company will gain access to the Ewing, NJ-based company's lead experimental blood cancer drug Vyxeos (CPX-351), which just last week gained an FDA “breakthrough therapy” designation.
The FDA’s designation--which speeds up its review of a new medicine--is for patients with therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
A recent Phase III trial met its primary endpoint by showing statistically significant improvement in overall survival; detailed data will be presented at ASCO next week.
Its current data for the drug showed median overall survival for patients treated with Vyxeos was 9.56 months compared with 5.95 months--a 3.61-month improvement in favor of Celator’s treatment against a chemotherapy agent known as 7+3.
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
www.globenewswire.com
C
Good news fellow Jazz enthusiast! I just noticed the executives buying LOTS of shares. Good sign for us!
N
feels nice to see this stock finally be in the profit for me
Divergency = a short emergency, 2 Massive Trial Results in 4 or 5 weeks and a Billion Dollar FDA Approval next year. SLS shares are Cheap As F - $50M Market cap when $jazz paid $1.5B for a direct comp, only a matter of time.
SLS has a MKT Cap of $113M vs $1.5B $JAZZ paid for $CPXX when it released its p3 data - GPS p3 data in months - equates to $95 Per SLS share. https://www.wsj.com/articles/jazz-pharmaceuticals-agrees-to-buy-celator-for-about-1-5-billion-1464686352
Cantor Fitz Analysts proj revenue of $200M in initial Niche cr2 setting.
SELLAS is a late-stage immune-oncology company that is focused on novel cancer vaccines. The lead drug candidate, galinpepimut-S (GPS), is a peptide vaccine that target Wilms tumor 1 and is in a Phase 3 trial for acute myeloid leukemia (AML).
Even in the initial niche target population of AML patients after second complete remission, “we project the peak sales to be about $200-million” Li Watsek
“Overtime, we think GPS has the potential to broaden into AML patients after first complete remission, as well as in other indications with combinations”
Gps is Priceless for AML patients. What will big pharma pay for $800M in Potential AML Revenue?
Buy and Hold
$17, then $70 and $170 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
The FDA’s designation--which speeds up its review of a new medicine--is for patients with therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
A recent Phase III trial met its primary endpoint by showing statistically significant improvement in overall survival; detailed data will be presented at ASCO next week.
Its current data for the drug showed median overall survival for patients treated with Vyxeos was 9.56 months compared with 5.95 months--a 3.61-month improvement in favor of Celator’s treatment against a chemotherapy agent known as 7+3.
Nps Twin Glsi trial, NPs license, Gps+Opdivo Meso trial data, and Gps + Keytruda ovarian cancer data unlocked.
$16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
$16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html